BioSapien is a biotechnology company specializing in innovative cancer treatments. Its flagship product, MediChip, is a 3D-printed, biodegradable implant designed to deliver chemotherapy drugs directly to tumor sites, aiming to minimize systemic side effects commonly associated with traditional chemotherapy. This localized approach targets cancer cells more precisely and enhances patients' quality of life during treatment. The company holds global patents for its platform, with expirations set for 2039. BioSapien's mission is to advance human well-being through innovative solutions, with a goal to treat over one million patients by 2035. In addition to Abu Dhabi, the company has an office in San Diego, California.
Founded 2018
Employees 15+
Primary contact
Abu Dhabi Global Market (ADGM)
Abu Dhabi
United Arab Emirates
Funding
💰
Total
$9.8M
Last round
🔗
~$1MPre-Series A extension
July 7, 2025.
Select investors Global Ventures, Dara Holdings,
HUB71, Hikma Ventures, SOSV, MicroVentures, Techstars, Golden Gate Ventures, Globivest
Highlights
⭐
Content in this section is available for DHArab Premium Members only. We manually enter this information so you can save time researching different companies.
Existing users 👉 click here to login
Looking to become a member? 👉 click here for more information
Quotes
💬
“
We are excited to lead BioSapien's pre-Series A fundraise and support Khatija's team in providing a pioneering and local solution to colorectal cancer. BioSapien's drug delivery technology utilizes advanced 3D printing and epitomizes cost-effective innovation in a market ripe for new solutions with benefits for multiple stakeholders - including the most important of all – patients. With the company's multiple competitive advantages, and the markets for colorectal and wider cancer treatments, BioSapien is at the forefront of advanced technological solutions to meet global demand.
— Noor Sweid, Founder & Managing Partner of Global Ventures
“
We look forward to supporting BioSapien as it disrupts the healthcare sector via innovation seeded from the region. Through localised delivery and using advanced 3D-printing, the company is providing an alternative to traditional cancer treatment. BioSapien's patented drug delivery platform - MediChip - increases the bioavailability and retention of the desired medication, meaning less is required. This in turn, has the potential to vastly improve the patient's treatment journey on a global scale.
— Sacha Haider, Partner at Global Ventures
“
As so many have witnessed or experienced first-hand, the effects of chemotherapy can take a tremendous toll on the immune system and body of patients undergoing treatment for cancer. We are excited to be an early investor in BioSapien and their novel drug delivery system, which has the potential to revolutionize the delivery of chemotherapy through a targeted, personalized, and controlled approach to alleviate the unwanted side effects and toxicities of the treatment.
— Hamzeh Abdul-Hadi, Principal at Hikma Ventures
🔗
“
Having met CEO and Founder Khatija at Hub71 in Abu Dhabi, we were instantly impressed by her passion and vision. Investing in BioSapien aligns with our commitment to supporting transformative technologies that address significant global challenges. This investment not only supports a groundbreaking technology but also reinforces the Gulf region's role as a global leader in healthcare innovation.
— Michael Lints, Partner at Golden Gate Ventures MENA
“
At Globivest, we back companies that don't just promise innovation - they deliver transformative, science-backed solutions with the power to shift paradigms. BioSapien's MediChip platform is a breakthrough in localized cancer treatment - scalable, precise, and deeply aligned with our One Health mission. We're proud to support Dr. Khatija Ali and her team as they build the future of accessible precision medicine.
— Dr. Laura-Joy Boulos, Partner at Globivest
Last update:
July 7, 2025
